- This topic is empty.
-
Posts
-
-
This page lists the main topics and stocks discussed on Mad Money with Jim Cramer aired on January 14, 2025, with links to CNBC articles, videos, and English transcripts.
2025年1月14日放送の 「Mad Money with Jim Cramer」 で取り上げられた主な話題・銘柄を、CNBCの記事・動画・英文トランスクリプトへのリンクとともに一覧化しています。
(1) Jim Cramer says he supports healthcare stocks for their long-term value (https://www.cnbc.com/2025/01/14/jim-cramer-eli-lilly-merck-regeneron.html)
- CNBC’s Jim Cramer on Tuesday opined on the importance of investing for the long term, telling investors it’s wise to evaluate certain pharmaceutical stocks for their growth prospects.
- “Ask yourself what happens if things get better, please. What if the future is brighter than the past?” he said. “If that’s the case, and I think it is, then you’ll have a lot of winners with these drug and medical device plays.”
(2) [No Video Clip for non-Club members] Executive Interview: We are probably one of the most diversified healthcare companies now, says Abbott Labs CEO Robert Ford (https://www.cnbc.com/video/2025/01/14/we-are-probably-one-of-the-most-diversified-healthcare-companies-now-says-abbott-labs-ceo-robert-ford.html)
Abbott Labs Chairman and CEO Robert Ford joins ‘Mad Money’ host Jim Cramer to talk its medical equipment offerings, the infant formula litigation, and more.
Ticker: ABT
(3) Executive Interview: Merck CEO talks medicines beyond the company’s top cancer drug (https://www.cnbc.com/2025/01/14/merck-ceo-talks-medicines-beyond-the-companys-top-cancer-drug.html)
- Merck Merck CEO Rob Davis told CNBC’s Jim Cramer that there’s more to the pharmaceutical giant than its lucrative cancer drug, Keytruda, and he described other ventures in its portfolio.
- “Keytruda has truly been transformational in the treatment of cancer,” he said. “But, importantly, we are now in a situation where we can really leverage the strength of Keytruda to go well beyond Keytruda.”
Ticker: MRK
(4) [No Video Clip for non-Club members] Executive Interview: Regeneron CEO Len Schleifer sits down with Jim Cramer (https://www.cnbc.com/video/2025/01/14/regeneron-ceo-len-schleifer-sits-down-with-jim-cramer.html)
Regeneron Co-Chair, President and CEO Len Schleifer joins ‘Mad Money’ host Jim Cramer at the JPMorgan Healthcare Conference to talk drug development, where he is seeing growth, quarterly results and more.
(5) Cramer’s Lightning Round: Super Micro Computer is a sell (https://www.cnbc.com/2025/01/14/cramers-lightning-round-super-micro-computer-is-a-sell.html)
- Dutch Bros: “I think Christine is doing a remarkable job at Dutch Bros.”
- Ardmore Shipping: “I’m not a fan of Ardmore Shipping. I’m not a fan of most of the container and, and just kind of commercial cargo ships because they tend to be too episodic for me. So I’m going to take a pass.”
- Super Micro Computer: “Sell. It doesn’t matter, I don’t care…Accounting irregularities equal sell.”
- FMC: “I love Philadelphia, but I can only rate that one a hold because I don’t like the sector it is in, crop chemicals, fungicide. No, I’m not there for that.”
Ticker: BROS, ASC, SMCI, FMC
(6) [No Video Clip for non-Club members] Executive Interview: We’re focused on taking care of our customers needs more than anyone else, says Cardinal Health CEO Jason Hollar (https://www.cnbc.com/video/2025/01/14/were-focused-on-taking-care-of-our-customers-needs-more-than-anyone-else-says-cardinal-health-ceo-jason-hollar.html)
Cardinal Health CEO Jason Hollar joins ‘Fast Money’ at the JPMorgan Healthcare Conference to talk AI integration, growth opportunities, and more.
Ticker: CAH
Other Stocks Discussed (calls with audience)/ この日の放送で取り上げられたその他の銘柄（視聴者からの電話): Tesla (TSLA) [buy more]
Ref: Links related to this episode /参考: この日の放送に関するその他のサイトへのリンク:
- Podcast at Spotify (Sound /音声）
- InternetArchive（Video & Texts per minute /1分毎のビデオ＆テキスト）
****************************
Previous Episode/ 前回のエピソード Next Episode / 次回のエピソード
-
- The forum ‘Mad Money Stock Archive (ジム・クレイマーの銘柄紹介)’ is closed to new topics and replies.